Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma

Not Applicable

Completed

Brief Summary: This study will use PET/MRI in patients with adenocarcinoma of the pancreas to identify hidden metastatic disease or identify patients with borderline or locally advanced disease.

Detailed Description: Patients will receive a PET/MRI scan within 6 weeks of their standard of care imaging. There is no maximum number of scans for research. The number of scans depends on each patient's treatment plan.

Recruitment & Eligibility

Inclusion Criteria

Presence of suspicious lesion of the pancreas consistent with pancreatic adenocarcinoma. Cytological confirmation is not required.
Patients preparing to receive therapy for pancreas cancer, including patients enrolled in NCT01413022
Patient must be 18 years or older
Patient must have a life expectancy of more than 6 months and performance status of 2 or less
Patient must be able to understand and willing to sign an approved written informed consent document
Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the length of the study
Patients enrolled in the Clinical trials.gov# NCT01413022 trial must meet both studies eligibility criteria.

Exclusion Criteria

Patient must not have had prior resection for pancreatic adenocarcinoma.
Patient must not have a history of other malignancy less than or equal to 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix
Patient must not be unable to receive a PET-MRI scan due to renal function, allergy or other problem with receiving or tolerating an MRI scan, etc. All patients will fill out a standard MRI screening form.
Patients must not have a blood glucose of greater than or equal to 200mg/dL at the time of PET-MRI or if a patient is diabetic and glucose is not controlled. At the discretion of the PI and the authorized user and with their approval prior to 2-[18]fluoro-2-deoxy-D-glucose (FDG) injection, patients with blood glucose ≥ 200 mg/dL may participate in the study.
Patient must not be pregnant and/or breast feeding

Arm && Interventions

Group	Intervention	Description
Imaging	PET/MRI	PET/MRI

Primary Outcome Measures

Name	Time	Method
PET/MRI compared to conventional CT and MRI	Up to several months or longer. Patient will undergo research imaging with each standard of care scan they have.	Primary outcome is to determine if the primary tumor and the margins of anatomical land marks from the PET/MRI imaging is more precise and gives a clearer picture of tumor location than standard care, CT or MRI. Both standard of care imaging and this new technology will be compared to the final pathologic analysis, measuring the true distance (in mm) between the primary tumor and margins. Data will be reported as mm.

Secondary Outcome Measures

Name	Time	Method
Resectability post neoadjuvant treatment	Several months or as deemed a surgical candidate by physician.	The secondary outcome is to determine if PET/MRI imaging is better than standard of care imaging (CT or MRI) after patients have received chemotherapy and to determine if they are surgical candidates. The objective is to determine if the primary tumor and the margins of anatomical land marks from the PET/MRI imaging is more precise and gives a clearer picture of tumor location than standard care, CT or MRI. Both standard of care imaging and this new technology will be compared to the final pathologic analysis, measuring the true distance (in mm) between the primary tumor and margins. Data will be reported as mm.

Locations (1): Washington Unviversity School of Medicine
🇺🇸
Saint Louis, Missouri, United States

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial